Related Experiment Video
Updated: Nov 20, 2025

04:11
Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
Published on: April 28, 2023
2.0K
Cochlear Implantation in Meniere's Disease: A Systematic Review and Meta-Analysis
Dillan F Villavisanis1, Maria A Mavrommatis1, Elisa R Berson2
1Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A.
The Laryngoscope
|January 19, 2021
Summary
Cochlear implantation (CoI) with or without labyrinthectomy offers a viable treatment for Meniere
Area of Science:
- Otolaryngology
- Neuroscience
- Audiology
Background:
- Meniere's disease (MD) is a chronic inner ear disorder causing debilitating hearing loss, vertigo, and tinnitus.
- Current treatments for MD often provide limited relief, necessitating exploration of advanced surgical options.
Purpose of the Study:
- To systematically review and meta-analyze outcomes of cochlear implantation (CoI) in patients diagnosed with Meniere's disease (MD).
- To evaluate the efficacy of CoI, with and without labyrinthectomy, in managing MD symptoms including hearing, vertigo, and tinnitus.
Main Methods:
- A systematic review and meta-analysis of studies identified through Medline and Embase databases.
- Inclusion criteria focused on patients with MD undergoing CoI, assessing outcomes in speech recognition, audiometry, vertigo, tinnitus, and quality of life.
Main Results:
- Analysis of 37 studies involving 216 MD patients revealed significant improvements in audiometric outcomes post-CoI.
- Statistically significant improvements were noted in speech recognition (Hearing in Noise Test, Freiburger Monosyllabic Test, Consonant-Nucleus-Consonant) and a significant reduction in tinnitus (Tinnitus Handicap Index).
Conclusions:
- Cochlear implantation (CoI), with or without labyrinthectomy, is a viable treatment for Meniere's disease (MD).
- This intervention effectively suppresses tinnitus and controls vertigo, with postoperative speech perception comparable to non-MD implant recipients.

